Aptar Reports Third Quarter 2021 Results
Third Quarter 2021 Summary *Reported sales grew 9%, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage from a combination of price increases and volume growth *Core sales (excluding currency effects) increased 8% *Pharma sales declined slightly compared to the prior year *Reported net income totaled $47 million *Acquisition Updates: -Completed the acquisition of 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery -Completed the acquisition of a majority stake in Voluntis, a provider of digital therapeutic solutions